Literature DB >> 12908659

Assessing clinical and functional outcomes in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial.

Marvin S Swartz1, Diana O Perkins, T Scott Stroup, Joseph P McEvoy, Jennifer M Nieri, David C Haak.   

Abstract

Schizophrenia is a symptomatically heterogeneous disorder characterized by the presence of positive and negative symptoms, and variable impairment in community functioning. Given the diversity of symptom presentations and functioning associated with schizophrenia, one of the key challenges facing the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial was the selection of efficient assessment measures appropriate to a community-based effectiveness trial. This article describes the rationale for the measurement approach adopted for the trial, provides a brief overview of the selected measures, and describes the process of training assessment raters for a large and geographically dispersed study group.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12908659     DOI: 10.1093/oxfordjournals.schbul.a006989

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  31 in total

Review 1.  Pharmacogenetics of antidepressants, mood stabilizers, and antipsychotics in diverse human populations.

Authors:  Eleanor Murphy; Francis J McMahon
Journal:  Discov Med       Date:  2013-09       Impact factor: 2.970

2.  Employment outcomes in a randomized trial of second-generation antipsychotics and perphenazine in the treatment of individuals with schizophrenia.

Authors:  Sandra G Resnick; Robert A Rosenheck; Jose M Canive; Cyril De Souza; T Scott Stroup; Joseph McEvoy; Sonia Davis; Richard S E Keefe; Marvin Swartz; Jeffrey Lieberman
Journal:  J Behav Health Serv Res       Date:  2008-02-02       Impact factor: 1.505

3.  Does improvement in symptoms and quality of life in chronic schizophrenia reduce family caregiver burden?

Authors:  Taeho Greg Rhee; Robert A Rosenheck
Journal:  Psychiatry Res       Date:  2018-12-03       Impact factor: 3.222

4.  Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study.

Authors:  Yan Feng; Bruce G Pollock; Kim Coley; Stephen Marder; Del Miller; Margaret Kirshner; Manickam Aravagiri; Lon Schneider; Robert R Bies
Journal:  Br J Clin Pharmacol       Date:  2008-07-31       Impact factor: 4.335

5.  Low dose vs standard dose of antipsychotics for relapse prevention in schizophrenia: meta-analysis.

Authors:  Hiroyuki Uchida; Takefumi Suzuki; Hiroyoshi Takeuchi; Tamara Arenovich; David C Mamo
Journal:  Schizophr Bull       Date:  2009-11-27       Impact factor: 9.306

6.  The Validity and Sensitivity of PANSS-6 in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Study.

Authors:  Søren D Østergaard; Leslie Foldager; Ole Mors; Per Bech; Christoph U Correll
Journal:  Schizophr Bull       Date:  2018-02-15       Impact factor: 9.306

7.  Q-learning residual analysis: application to the effectiveness of sequences of antipsychotic medications for patients with schizophrenia.

Authors:  Ashkan Ertefaie; Susan Shortreed; Bibhas Chakraborty
Journal:  Stat Med       Date:  2016-01-10       Impact factor: 2.373

8.  Time to discontinuation of antipsychotic drugs in a schizophrenia cohort: influence of current treatment strategies.

Authors:  Rune A Kroken; Eirik Kjelby; Tore Wentzel-Larsen; Liv S Mellesdal; Hugo A Jørgensen; Erik Johnsen
Journal:  Ther Adv Psychopharmacol       Date:  2014-12

9.  What CATIE found: results from the schizophrenia trial.

Authors:  Marvin S Swartz; T Scott Stroup; Joseph P McEvoy; Sonia M Davis; Robert A Rosenheck; Richard S E Keefe; John K Hsiao; Jeffrey A Lieberman
Journal:  Psychiatr Serv       Date:  2008-05       Impact factor: 3.084

10.  Cross-sectional and longitudinal relationships between insight and attitudes toward medication and clinical outcomes in chronic schizophrenia.

Authors:  Somaia Mohamed; Robert Rosenheck; Joseph McEvoy; Marvin Swartz; Scott Stroup; Jeffrey A Lieberman
Journal:  Schizophr Bull       Date:  2008-06-26       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.